글로벌 뇌졸중 진단 시장 – 2031년까지의 산업 동향 및 예측

뇌졸중 진단 시장 분석 및 규모

뇌졸중 진단은 뇌혈관 사건을 정확하게 식별하고 평가하는 데 중요한 역할을 합니다. MRI 및 CT 스캔과 같은 영상 기술과 임상 평가를 활용하여 이러한 진단은 뇌졸중의 유형, 심각도 및 위치를 결정하고 최적의 환자 결과를 위한 시기적절하고 맞춤화된 치료 전략을 안내하는 데 도움이 됩니다.                            

Data Bridge Market Research는 2023년에 3,839.94백만 달러였던 글로벌 뇌졸중 진단 시장이 2031년까지 6,548.57백만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 6.9%의 CAGR을 보일 것으로 예상된다고 분석했습니다. 이는 시장 가치를 나타냅니다. "컴퓨터 단층 촬영(CT 스캔)"은 CT 스캔 기술의 지속적인 향상으로 인해 뇌졸중 진단 시장의 유형 세그먼트를 지배할 것으로 예상되며, 의료 전문가에게 뇌졸중 진단에 대한 정확하고 자세한 통찰력을 제공하여 시장 성장에 영향을 미칩니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

뇌졸중 진단 시장 범위 및 세분화

시장 정의

뇌졸중 진단에는 뇌졸중을 식별하고 평가하는 다양한 기술이 포함됩니다. 뇌졸중은 뇌로의 혈류가 중단되는 것을 특징으로 하는 의학적 응급 상황입니다. 진단 방법에는 CT 스캔 및 MRI와 같은 영상 검사, 혈액 검사 및 신경학적 검사가 포함됩니다. 뇌졸중 환자의 신속한 개입과 효과적인 관리를 위해서는 조기에 정확한 진단이 중요합니다.

글로벌 뇌졸중 진단 시장 역학

운전자

• 진단 도구에 AI와 ML 통합

AI와 머신러닝을 진단 도구에 통합하면 뇌졸중 진단 시장이 촉진됩니다. 이러한 기술은 정교하고 빠른 분석을 가능하게 함으로써 뇌졸중 진단의 정확성과 효율성을 향상시키고, 의료 전문가에게 고급 통찰력을 제공하고, 환자 결과를 개선하며, 시장 성장을 촉진합니다.

• 노령 인구에서 뇌졸중 발생률 증가

The growing aging population significantly fuels the stroke diagnostics market, correlating with an elevated incidence of strokes among the elderly. This demographic trend emphasizes the increasing need for advanced diagnostic tools and services to address the higher vulnerability of the aging population to stroke-related health challenges.

Opportunities

• Growing Healthcare Expenditure in  Developed Regions

Higher healthcare spending in developed regions enables broader accessibility to advanced diagnostic services, fueling market growth for stroke diagnostics. With increased financial resources allocated to healthcare, patients have greater access to state-of-the-art diagnostic technologies, enhancing early detection and treatment of cerebrovascular events such as strokes.

• Personalized Medicine in Stroke Diagnostics

Advancements in personalized medicine revolutionize stroke diagnostics, enabling customized approaches. Tailored diagnostic strategies consider an individual's unique genetic and molecular characteristics, enhancing the precision of stroke detection and management. This personalized approach optimizes treatment plans, fostering more effective interventions and improving outcomes for patients with strokes. 

Restraints/Challenges

• High Cost of Diagnostic Imaging Technologies

The high cost of advanced diagnostic imaging technologies, notably MRI and CT scans, acts as a significant impediment to the widespread adoption of stroke diagnostics. This financial barrier, particularly in resource-limited healthcare settings, restricts accessibility and hampers the market's potential for broader utilization and improved patient outcomes. 

• Risk of Radiation Exposure in Imaging Technologies

The risk of radiation exposure, notably in repeated CT scans, poses a challenge for the stroke diagnostics market. Concerns about potential harm may lead to hesitancy among healthcare providers and patients, influencing the frequency of use of diagnostic imaging technologies and potentially impacting timely stroke diagnosis and treatment decisions.

This global stroke diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global stroke diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In May 2021, Siemens launched the Somatom X.ceed, a high-resolution, high-speed CT scanner designed for challenging clinical areas. This innovation enhances Siemens' product pipeline, delivering their commitment to advancing diagnostic imaging technologies. The Somatom X.ceed is tailored to deliver precise and efficient imaging, catering to the complex demands of diverse clinical scenarios
• In April 2021, the FDA authorized the Neurolutions IpsiHand Upper Extremity Rehabilitation System by Neurolutions, Inc. This Brain-Computer-Interface (BCI) device facilitates rehabilitation for stroke patients with upper extremity disabilities, specifically addressing hand, wrist, and arm impairments. The approval underscores its potential in enhancing neurorehabilitation outcomes for individuals recovering from stroke-related motor deficits
• In April 2021, Koninklijke Philips N.V. announced a strategic partnership with Ibex Medical Analytics to collectively advance their digital pathology and A.I. solutions globally. This collaboration aims to strengthen their distribution channels, facilitating enhanced accessibility to innovative pathology solutions for hospitals, health networks, and pathology labs worldwide
• In September 2020, Hyperfine Research, Inc. obtained FDA 510(k) clearance for their groundbreaking Swoop Portable MR imaging device. This portable MRI technology redefines point-of-care imaging, allowing for on-the-spot magnetic resonance imaging. The FDA clearance signifies a significant advancement, enabling more accessible and immediate diagnostic imaging in diverse healthcare settings
• In June 2020, RapidAI achieved FDA clearance for artificial intelligence algorithms capable of swiftly analyzing brain CT scans, identifying suspected large vessel occlusions—a leading cause of severe strokes. Additionally, they obtained FDA clearance for computer-assisted diagnostic software, enhancing physicians' interpretation of non-contrast CT scans, reflecting advancements in stroke diagnostics technology

Global Stroke Diagnostics Market Scope

The global stroke diagnostics market is segmented on the basis of severity, type, technology, application, end user, distribution channel, and stage. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Severity

• Moderate
• Severe
• Mild

Type

• Diagnostics
• Therapeutics
• Tissue Plasminogen Activator
•  Antiplatelet
• Antihypertensive
•  Anticoagulant
• Software

 Technology

• Computed Tomography (CT Scan)
• Computed Tomography Angiography (CTA)
• Magnetic Resonance Imaging (MRI)
• Magnetic Resonance Angiography (MRA)
• Transcranial Doppler Ultrasound
• Video Head Impulse Test (VHIT)
• Electrocardiography
• Carotid Ultrasound
• Cerebral Angiography
• Others

 Application

• Ischemic Stroke
• Hemorrhagic Stroke
• Transient Ischemic Attacks (TIAS)

 End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Home Healthcare

 Distribution Channel

• Direct Tender
• Third Party Distributors
• Others

Stage

• Pre Operative
• Peri Operative
• Post Operative

Global Stroke Diagnostics Market Regional Analysis/Insights

The global stroke diagnostics market is analysed and market size insights and trends are provided by country, severity, type, technology, application, end user, distribution channel, and stage as referenced above.

The countries covered in the global stroke diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the global stroke diagnostics market, propelled by the largest consumer market and a high GDP. The U.S., in particular, is poised to lead with advancements in technology and a rising incidence of strokes. This region's economic strength and healthcare innovation contribute significantly to its prominence in stroke diagnostics.

Europe is expected to dominate the global stroke diagnostics market, with Germany emerging as a key contributor to promising growth rates forecasted from 2024 to 2031. This upsurge is attributed to heightened research and development endeavors, positioning the region as a frontrunner in advancing stroke diagnostic technologies and practices.

Asia-Pacific is expected to dominate the global stroke diagnostics market from 2024 to 2031, driven by leading countries such as Japan. With a surge in product usage and advancements in product development, Japan is anticipated to take the lead, emphasizing the region's pivotal role in shaping the landscape of stroke diagnostics worldwide.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

글로벌 뇌졸중 진단 시장은 또한 모든 국가에 대한 자세한 시장 분석을 제공합니다. 자본 장비에 대한 의료 지출 증가, 글로벌 뇌졸중 진단 시장을 위한 다양한 종류의 제품 설치 기반, 수명선 곡선을 사용하는 기술의 영향, 의료 규제 시나리오의 변화 및 글로벌 뇌졸중 진단 시장에 미치는 영향. 이 데이터는 2016-2021년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 글로벌 뇌졸중 진단 시장 점유율 분석

글로벌 뇌졸중 진단 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 글로벌 뇌졸중 진단 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 뇌졸중 진단 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 지멘스 헬스케어 GmbH(독일)
• Koninklijke Philips NV(네덜란드)
•  GE 헬스케어(미국)
•  Mindray Medical India Pvt. Ltd. (인도)
•  후지필름 주식회사(일본)
•  CANON MEDICAL SYSTEMS CORPORATION(일본)
•   알피니언 메디컬 시스템 주식회사(한국)
•  아날로직 코퍼레이션(미국)
•  Aspect Imaging Ltd. (미국)
•  BPL Medical Technologies (인도)
•  케어스트림 헬스(미국)
•  에사오테스파(이탈리아)
•  FONAR Corp. (미국)
•  홀로직 주식회사(미국)
•  IMRIS Inc. (캐나다)
•  Medfield Diagnostics AB. (스웨덴)
•  MEDTRON AG(독일)  

SKU-40260